Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T21:13:58.296Z.
Calculation as of: 2026-10-06T21:13:58.296Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b7fd3b5d8e417d78924f6cd313032c2aac5600bd184120b35a4860f29c1b1599
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$71.23M
EV/Sales Ratio
N/A
TTM Avg
622.59x
3Y Avg
533.68x
5Y Avg
749.31x
Market Cap
$69.61M
EV/Sales Ratio
1.26x
TTM Avg
1.43x
3Y Avg
1.60x
5Y Avg
1.76x
Market Cap
$72.32M
EV/Sales Ratio
2.08x
TTM Avg
2.66x
3Y Avg
16.97x
5Y Avg
40.94x
Market Cap
$68.90M
EV/Sales Ratio
0.47x
TTM Avg
1.76x
3Y Avg
1.34x
5Y Avg
5.36x
Market Cap
$72.83M
EV/Sales Ratio
5.96x
TTM Avg
4.80x
3Y Avg
3.21x
5Y Avg
3.97x
Market Cap
$68.10M
EV/Sales Ratio
N/A
TTM Avg
1.19x
3Y Avg
0.71x
5Y Avg
0.83x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tiziana Life Sciences Ltd (TLSA) | $70.63M | N/A | N/A | N/A | N/A |
| Gain Therapeutics, Inc. (GANX)vs › | $71.23M | N/A | 622.59x | 533.68x | 749.31x |
| Champions Oncology, Inc. (CSBR)vs › | $69.61M | 1.26x | 1.43x | 1.60x | 1.76x |
| Verrica Pharmaceuticals Inc. (VRCA)vs › | $72.32M | 2.08x | 2.66x | 16.97x | 40.94x |
| Spero Therapeutics, Inc. (SPRO)vs › | $68.90M | 0.47x | 1.76x | 1.34x | 5.36x |
| MindWalk Holdings Corp. (HYFT)vs › | $72.83M | 5.96x | 4.80x | 3.21x | 3.97x |
| Fortress Biotech, Inc. (FBIO)vs › | $68.10M | N/A | 1.19x | 0.71x | 0.83x |
| Hyperfine, Inc. (HYPR)vs › | $73.27M | 2.61x | 6.00x | 3.83x | 57.38x |
| iBio, Inc. (IBIO)vs › | $67.52M | 133.26x | 409.50x | 278.27x | 209.69x |
| Pulmonx Corporation (LUNG)vs › | $75.18M | 0.86x | 0.66x | 2.48x | 6.11x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
